GSK was the standout laggard on the FTSE 100, sinking 6.2% after a US Food & Drug Administration advisory panel voted against approving its cancer drug Blenrep at the proposed dosage. Although the FDA ...

U.S. futures for the S&P 500 were up 0.1% and futures for the Dow Jones Industrial Average rose 0.2%. Changes in futures do not necessarily predict movements after the opening bell.

According to reports, the USFDA's Oncologic Advisory Committee voted that the risks from the drug, called Blenrep, outweighed ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...

(Sharecast News) - London stocks rose in early trade on Friday, taking their cue from a positive close on Wall Street, where the S&P 500 and Nasdaq hit new highs. At 0825 BST, the FTSE 100 was up 0.2% ...

GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug ...

"GSK remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple ...

Mistral added deep research capabilities to its Le Chat platform, bringing it in direct competition against ChatGPT and ...

The median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...

Investing.com -- GSK (LON:GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

US FDA approves GSK’s Shingrix in a prefilled syringe presentation for prevention of shingles: London, UK Friday, July 18, 2025, 09:00 Hrs [IST] GSK plc announced that the US Fo ...